Africa Challenges Biomedical Imperialism in Health Agreements. City, Country — Harare, Zimbabwe — The United States’ expanding network of health partnerships with African nations has sparked controversy, raising concerns about biomedical imperialism. Late last month, Zimbabwe pulled out of a proposed $367m health funding agreement, citing terms that demanded extensive access to sensitive health data without guaranteed equitable access to resulting medical technologies.
The five — year programme, aimed at combating HIV/AIDS, tuberculosis, malaria, and epidemic preparedness, was seen by Zimbabwe as an unequal exchange. Critics argue that such agreements resemble biomedical extractivism, characterized by exploitative research practices and colonial thinking, reinforcing Western dominance.
In Zambia, officials and civil society groups have expressed similar concerns about a proposed $1bn health partnership with the United States.
The draft agreement requires Zambia to contribute around $340m while granting the U. S. Extensive access to national health data and pathogen-sharing arrangements.
These disputes come amidst the backdrop of the “America First Global Health Strategy,” under which the U. S. Has signed more than 20 memoranda of understanding with African governments, with total commitments approaching $20bn.
The Kaiser Family Foundation, a U. S. -based health policy research organization, has tracked these agreements, which span implementation timelines from 2026 to 2030.
While these pacts fund programmes against various diseases and strengthen health systems, they shift bargaining power towards Washington. For example, Nigerian funding is contingent on the government prioritizing the protection of Christian populations from violence.
The central controversy lies in the U.
S. ’s expectation of health data and pathogen samples in return.
This information is crucial for global biotechnology and pandemic preparedness, valued as highly as oil, minerals, or rare earths.
African countries, as potential upstream suppliers of biological information, fear that downstream benefits, such as intellectual property and pharmaceutical manufacturing, will remain concentrated in wealthier nations. This concern echoes a history in which medicine in Africa has been intertwined with imperial power and foreign domination.
Colonial medical campaigns often combined disease control with surveillance and coercive governance.
Modern ethical controversies involving Western pharmaceutical companies have further fueled skepticism.
The global biotechnology sector generates over $1. 5 trillion annually, and genomic data and pathogen samples are among the most valuable scientific resources of the 21st century.
Ethical researchers argue that international medical research must avoid exploiting populations in low and middle — income countries.
African countries face a delicate balancing act: safeguarding life-saving health programmes while defending data sovereignty and reciprocal partnerships. Collective negotiation through institutions like the African Union and the Africa Centres for Disease Control and Prevention may offer a solution.
The U. S. Has since moved to wind down its health funding in Zimbabwe following the collapse of negotiations, highlighting the risks for other African countries that resist these terms.
Only united action can prevent powerful states from imposing new forms of imperial control through country — specific accords.
The United States must ensure that, if Africa shares its data and samples, it reciprocates on equal and transparent terms.
The stakes are high, and the future of African health and global biotechnology hangs in the balance.
